The label expansion for Boehringer Ingelheim’s Hernexeos was made under an FDA pilot program that accelerates regulatory review of products with national interest. The daily pill is now approved as a first-line treatment for HER2-positive non-small lung cancer, an indication with few treatment options.
The post FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer appeared first on MedCity News.
